It is my privilege to invite you to the International Extracellular Matrix Pharmacology Congress – ECM2024 – from 17-19 June 2024 in Copenhagen, Denmark.
It is clear to me that the extracellular matrix is a common denominator across most chronic diseases, and that we need a forum for this research.
Connective tissue turnover in an imbalance, showing either elevated degradation or formation of tissue, is a universal characteristic in all chronic diseases and we need to zoom in on the extracellular matrix across disease indications.
I think it is essential for the benefit of patients and drug development to place research focus and attention on the extracellular matrix. Tissue formation and tissue destruction in the immune-inflammatory space are central drivers of many diseases and we must start to learn from other disease fields where fibrosis and tissue destruction are also central components.
ECM2024 will bring together experts from different organ diseases: liver, lung, kidney, skin, cardiovascular, cancer (tumor fibrosis), and immunology, in which the central common denominator is the ECM. We aim to cross-fertilize and assist drug development to help the lives of patients. The center is extracellular matrix pharmacology, and how its modulation can help patients.
ECM2024 will offer an unforgettable mix of networking and state-of-the-art research with a wide range of internationally renowned extracellular matrix experts.
We hope to see you at ECM2024.
Morten Karsdal, PhD, Professor